Bou Trade Labs, SL

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Bou Trade Labs, SL - overview

Established

2016

Location

Madrid, -, Spain

Primary Industry

Healthcare

About

Bou Trade Labs, SL operates as a biotechnology company specializing in DNA testing services, offering customers insights into health, ancestry, and nutrition through analysis of genetic material. Founded in 2016 and headquartered in Madrid, Spain, Bou Trade Labs, SL provides DNA testing services that assess various genetic traits. The company has engaged in one funding round, raising EUR 1. 1 million in December 2020 from Capital Cell Investors, achieving a current company valuation of EUR 9.


00 mn. The CEO is Nacho Esteban, who leads the company in its operations and strategic direction. 24Genetics specializes in comprehensive DNA testing services that provide insights into various aspects of an individual's genetics, including ancestry, health, nutrition, sports performance, and personality traits. Their core product offerings include a DNA testing kit that allows users to collect saliva samples at home, which are then analyzed in their labs to produce detailed genetic reports.


The tests reveal genetic predispositions to health conditions, optimal diets, and personalized training regimens, serving a diverse client base across more than 100 countries. In 2023, Bou Trade Labs, SL reported a revenue of EUR 1,139,041. 20, with an EBITDA of EUR -9,457. 70 for the same year.


The company generates revenue primarily through direct-to-consumer sales of its DNA testing kits and associated reports, focusing on B2C interactions. Bou Trade Labs, SL plans to leverage its recent funding of EUR 1. 1 million, raised in December 2020, to expand its product offerings and geographic reach. The company is developing new DNA testing products aimed at enhancing customer experience and engagement, with anticipated releases in the upcoming year.


Additionally, there are plans to penetrate new markets beyond its current presence, targeting specific regions and demographics to increase accessibility to its services.


Current Investors

Capital Cell Investors

Primary Industry

Healthcare

Sub Industries

Bioinformatics, Molecular Science, Genetics & Gene Therapy, Healthcare IT

Website

www.24genetics.com

Verticals

HealthTech

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.